Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al. Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • In the U.S., new cancer drugs have increased life expectancy at birth by 10.7%.  
  • Over the next 10 years, the number of cancer survivors in the U.S. is predicted to grow from 14.5 million to nearly 19 million (9.3 million men and 9.6 million…  
  • Between 2008 and 2010, use of colonoscopy for the treatment and prevention of colon cancer saved an average of $150,364 each year, per person affected.  
  • If the use of recommended colorectal screening increased to 70.5 percent, 1,000 additional lives could be saved each year.  
  • Mortality rates for colorectal cancer have declined over the past 2 decades and have had a steeper decline in the most recent time period (1.8% per year from 1985-2002 compared…